Japan Posts Draft Guidance On Biosimilars; Seeks Public Comment
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Japan's Ministry of Health, Labor and Welfare Sept. 17 posted draft guidance on follow-on biologics, or biosimilars, a move that could make Japan among the first group of large economies to set a safety and regulatory framework for the new copycat breed of biologic therapies
You may also be interested in...
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012
Merck Eyes Emerging Biosimilars Market In Japan
The company's Japanese subsidiary Banyu Pharmaceutical has started domestic trials for its generic erythropoietin, poised to be Merck's first biosimilar launch.